## Background: Interleukin 6 (il-6) is a b-cell growth and differentiation factor, which may promote the growth of b-cell neoplasms. in chronic lymphocytic leukemia (cll) patients, il-6 plasma levels increased in a stage-dependent manner, suggesting that il-6 may be a useful prognostic marker. the
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia
โ Scribed by Tait D. Shanafelt; Kari G. Rabe; Neil E. Kay; Clive S. Zent; Diane F. Jelinek; Megan S. Reinalda; Susan M. Schwager; Debbie A. Bowen; Susan L. Slager; Curtis A. Hanson; Timothy G. Call
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 371 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. Although patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary malignancies, including lung carcinoma, there is virtually no information about their clinical outcomes. To evaluate this, the authors reviewed their 20-year institutional e
The natural history of chronic lymphocytic leukemia (CLL) is changing, although the reasons (potential changes in the disease's biology or in patterns in patient characteristics, treatment, or referral) are unclear. ## METHODS. This report uses National Cancer Data Base (NCDB) data, which reflect
## Abstract Lymphocytes were isolated from the peripheral blood of 15 normal persons, 15 patients with chronic lymphocytic leukemia (CLL), 10 patients with Hodgkin's disease and 3 patients with CLL in remission. The cells were studied for cap formation and agglutinability by concanavalin A, and for